Development of a Cx46 targeting strategy for cancer stem cells
E. E. Mulkearns-Hubert, L. A. Torre-Healy, D. J. Silver, J. T. Eurich, E. Serbinowski, M. Hitomi, J. Zhou, B. Przychodzen, R. Zhang, S. A. Sprowls, J. S. Hale, T. Alban, A. Berezovsky, B. A. Bell, P. R. Lockman, , J. D. Lathia
This study identifies clofazimine as a Cx46 inhibitor that targets glioblastoma cancer stem cells by disrupting gap junction communication, enhancing the efficacy of temozolomide.
bioRxiv · Mar 26, 2018Cancer Biology